Restoration of estrogen responsiveness by blocking the HER-2/neu pathway

Oncology Reports

Volumn 9, Issue 6, 2002, Pages 1163-1166

  Witters, Lois ^a   Engle, Linda ^a   Lipton, Allan ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; Estrogen; HER 2 neu; Tamoxifen

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; MONOCLONAL ANTIBODY; TAMOXIFEN; TRASTUZUMAB;

ARTICLE; BREAST TUMOR; CELL CULTURE; CELL DIVISION; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; FEMALE; HUMAN; IMMUNOLOGY; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL DIVISION; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; FEMALE; HUMANS; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0036835014     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.9.6.1163     Document Type: Article

References (21)

1. Liu Y, El-Ashry D, Chen D, Ding IYF and Kern FG: MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Res and Treat 34: 97-117, 1995.
2. Gusterson BA: Identification and interpretation of epidermal growth factor and c-erbB-2 overexpression. Eur J Cancer 28: 263-267, 1992.
3. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989. (Pubitemid 19147683)
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987. (Pubitemid 17231334)
5. Perren TJ: cv-erbB-2 oncogene as a prognostic marker in breast cancer. Br J Cancer 63: 328-332, 1991.
6. Gullick WJ, Love SB, Wright C, Barnes DM, Gusterson B, Harris AL and Altman DG: c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 63: 434-438, 1991.
7. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX and Slamon DJ: HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10: 2435-2446, 1995.
8. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM and Osborne CK: Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER-2/neu. Breast Cancer Res Treat 24: 85-95, 1993.
9. Kurokawa H, Lenferink AE, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT and Arteaga CL: Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 60: 5887-5894, 2000.
10. Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Ryden S and Sigurdsson H: ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 81: 137-144, 1994. (Pubitemid 24184647)
11. Warri AM, Laine AM, Majasuo KE, Alitalo KK and Harkonen PL: Estrogen suppression of ERBB2 expression is associated with increased growth rate of ZR-75-1 human breast cancer cells in vitro and in nude mice. Int J Cancer 49: 616-621, 1991.
12. Antoniotti S, Maggiora P, Dati C and De Bortoli M: Tamoxifen up-regulates c-erbB-2 expression in oestrogen-responsive breast cancer cells in vitro. Eur J Cancer 28: 318-321, 1992.
13. Dati C, Antoniotti S, Taverna D, Perroteau I and De Bortoli M: Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells. Oncogene 5: 1001-1006, 1990.
14. Read KD, Keith D, Slamon DJ and Katzenellenbogen BS: Hormonal modulation of HER-2/neu proto-oncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res 50: 3947-3951, 1990. (Pubitemid 20225611)
15. Newby JC, Johnston SRD, Smith IE and Dowsett M: Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 3: 1643-1651, 1997. (Pubitemid 27431575)
16. Clark GM and McGuire WL: Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 15: 20-25, 1988.
17. Wright C, Nicholson S, Angus B, Sainsbury JRC, Farndon J, Cairns J, Harris AL and Horne C: Relationship between c-erbB2 protein expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65: 1188-1121, 1992.
18. Leitzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossbuerg H, Harvey H, Demers L and Lipton A: Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13: 1129-1135, 1995.
19. Lupu R and Lippman ME: The role of erbB-2 signal transduction pathways in human breast cancer. Breast Cancer Res Treat 27: 83-93, 1993. (Pubitemid 23316947)
20. Witters LM, Kumar R, Chinchilli VM and Lipton A: Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody. Breast Cancer Res Treat 42: 1-5, 1997. (Pubitemid 27056722)
21. Lin RJ, Brink J, Xuan JA and Langton-Weber BC: An antibody directed against the c-erbB-2 protein enhances the inhibitory activity of tamoxifen against estrogen-dependent c-erbB-2 expressing breast tumor cell lines. Breast Cancer Res Treat 32: (Suppl, abs.9), 31, 1994.